SCHEMBL2675552

SCHEMBL2675552

O=C(O)c1c(CNC2CC2)n(-c2ccccc2)c(=O)c2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HTR3E A5X5Y0 2/20 0.42
HTR3B O95264 2/20 0.42
HTR3A P46098 2/20 0.42
HTR3D Q70Z44 2/20 0.42
HTR3C Q8WXA8 2/20 0.42
THRB P10828 1/20 0.40
KDM4E B2RXH2 4/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
EGLN1 Q9GZT9 2/20 0.38
VEGFA P15692 1/20 0.38
MAPT P10636 2/20 0.36
KMT2A Q03164 1/20 0.36
RECQL P46063 1/20 0.36
TP53 P04637 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676530 0.95 KDM4E (0.43) MAPK1NPSR1L3MBTL1HTR3EHTR3B
SCHEMBL2675405 0.95 KDM4E (0.46) MAPK1NPSR1L3MBTL1HTR3EHTR3B
SCHEMBL2676570 0.94 KDM4E (0.47) MAPK1NPSR1L3MBTL1HTR3EHTR3B
SCHEMBL2677117 0.85 THRB (0.40) NPSR1HTR3EHTR3BHTR3AHTR3D
SCHEMBL2677075 0.84 MAPK1 (0.42) MAPK1NPSR1L3MBTL1HTR3EHTR3B
SCHEMBL2676271 0.82 ESRRA (0.46) MAPK1NPSR1L3MBTL1HTR3EHTR3B
SCHEMBL2677820 0.82 MAPK1 (0.47) MAPK1NPSR1L3MBTL1HTR3EHTR3B
SCHEMBL1717156 0.81 TACR3 (0.44) MAPK1NPSR1KDM4ETSHRKMT2A
SCHEMBL2675896 0.80 MAPK1 (0.45) MAPK1NPSR1L3MBTL1KDM4ETSHR
SCHEMBL2676762 0.79 MAPK1 (0.44) MAPK1NPSR1L3MBTL1HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 MAPK1 2750/4885NPSR1 182/4885L3MBTL1 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.